The latter finding suggests the hypothesis that, during RYGB-induced weight loss, chemerin might be involved in the amelioration of obesity-related hepatic fibrosis occurring during RYGB-induced weight loss, presumably in a protective role, as is illustrated in Figure 8. This evidence concerns the gene RARRES2 and Hepatic fibrosis.